Circulating miRNAs with prognostic value in metastatic breast cancer and for early detection of metastasis
Standard
Circulating miRNAs with prognostic value in metastatic breast cancer and for early detection of metastasis. / Madhavan, Dharanija; Peng, Cike; Wallwiener, Markus; Zucknick, Manuela; Nees, Juliane; Schott, Sarah; Rudolph, Anja; Riethdorf, Sabine; Trumpp, Andreas; Pantel, Klaus; Sohn, Christof; Chang-Claude, Jenny; Schneeweiss, Andreas; Burwinkel, Barbara.
in: CARCINOGENESIS, Jahrgang 37, Nr. 5, 2016, S. 461 - 470.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Circulating miRNAs with prognostic value in metastatic breast cancer and for early detection of metastasis
AU - Madhavan, Dharanija
AU - Peng, Cike
AU - Wallwiener, Markus
AU - Zucknick, Manuela
AU - Nees, Juliane
AU - Schott, Sarah
AU - Rudolph, Anja
AU - Riethdorf, Sabine
AU - Trumpp, Andreas
AU - Pantel, Klaus
AU - Sohn, Christof
AU - Chang-Claude, Jenny
AU - Schneeweiss, Andreas
AU - Burwinkel, Barbara
N1 - © The Author 2016. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.
PY - 2016
Y1 - 2016
N2 - Metastasis is the principal cause of high morbidity and mortality among breast cancer (BC) patients. Identification of markers that can be routinely monitored to predict onset of metastasis in BC patients and prognosis of metastatic breast cancer (MBC) patients would increase their median survival. In the present study, plasma miRNAs of 40 MBC patients were profiled by TaqMan low density arrays and miRNAs with prognostic capacity were identified. The candidates were validated initially in the samples of 237 MBC patients and subsequently in 335 samples from an independent study cohort of BC patients. Sixteen miRNAs were established to be significantly associated with overall survival, and were termed as prognostic miRNA panel template (PROMPT). These included miR-141, miR-144, miR-193b, miR-200a, miR-200b, miR-200c, miR-203, miR-210, miR-215, miR-365, miR-375, miR-429, miR-486-5p, miR-801, miR-1260, and miR-1274a. Additionally, eleven of these miRNAs were also associated with progression-free survival. Their prognostic significance was further confirmed in samples from a second study cohort of BC patients. In addition, miR-200a, miR-200b, miR-200c, miR-210, miR-215, and miR-486-5p were found to be significantly associated with onset of metastasis up to 2 years prior to clinical diagnosis in BC patients. We have thus identified panels of miRNAs, which include metastasis promoting miR-200 family and miR-203, as well as oncogenic and tumor suppressive miRNAs, that can serve as prognostic markers for MBC, and early detection markers of metastasis in BC.
AB - Metastasis is the principal cause of high morbidity and mortality among breast cancer (BC) patients. Identification of markers that can be routinely monitored to predict onset of metastasis in BC patients and prognosis of metastatic breast cancer (MBC) patients would increase their median survival. In the present study, plasma miRNAs of 40 MBC patients were profiled by TaqMan low density arrays and miRNAs with prognostic capacity were identified. The candidates were validated initially in the samples of 237 MBC patients and subsequently in 335 samples from an independent study cohort of BC patients. Sixteen miRNAs were established to be significantly associated with overall survival, and were termed as prognostic miRNA panel template (PROMPT). These included miR-141, miR-144, miR-193b, miR-200a, miR-200b, miR-200c, miR-203, miR-210, miR-215, miR-365, miR-375, miR-429, miR-486-5p, miR-801, miR-1260, and miR-1274a. Additionally, eleven of these miRNAs were also associated with progression-free survival. Their prognostic significance was further confirmed in samples from a second study cohort of BC patients. In addition, miR-200a, miR-200b, miR-200c, miR-210, miR-215, and miR-486-5p were found to be significantly associated with onset of metastasis up to 2 years prior to clinical diagnosis in BC patients. We have thus identified panels of miRNAs, which include metastasis promoting miR-200 family and miR-203, as well as oncogenic and tumor suppressive miRNAs, that can serve as prognostic markers for MBC, and early detection markers of metastasis in BC.
U2 - 10.1093/carcin/bgw008
DO - 10.1093/carcin/bgw008
M3 - SCORING: Journal article
C2 - 26785733
VL - 37
SP - 461
EP - 470
JO - CARCINOGENESIS
JF - CARCINOGENESIS
SN - 0143-3334
IS - 5
ER -